The advisors in Haya Therapeutics’s funding round
Swiss precision medicines company Haya Therapeutics completed a $65 million series A funding round. In connection with the deal, Kellerhals Carrard represented lead investors Sofinnova Partners and Earlybird Venture Capital, while Lenz & Staehelin assisted Eli Lilly, also amongst the investors participating to the round.
Moreover, ATHOS, +ND Capital, Alexandria Venture Investments and LifeLink Ventures took part to the operation, with additional support from existing investors Apollo Health Ventures, Longview Ventures (an affiliate of Broadview Ventures), 4see ventures, BERNINA Bioinvest and Schroders Capital.
Haya Therapeutics
Headquartered at the life sciences park Biopôle in Lausanne, Haya Therapeutics is a precision medicines company which specialises in RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions.
The Kellerhals Carrard team
Nicolas Mosimann (VC/life sciences, pictured above) led the Kellerhals Carrard team, working alongside Marco Sibold (tax), Kevin MacCabe (corporate/VC), Sebastian Müller (corporate/VC), Jan Bläuer (corporate/VC) and Danijel Gajic (corporate/VC).
The Lenz & Staehelin team
The Lenz & Staehelin team working on the matter included Tino Gaberthüel (pictured left), Patrick Schärli (pictured right), Arnold Romero and Kaan Saritas (all M&A), Lukas Aebi (tax) and Franziska Stadtherr-Glättli (management incentive plans).
